Positive selection of CD34 ؉ cells is being increasingly performed to support hematological reconstitution following high-dose and dose-intensive chemotherapy and to reduce the non-target cell content of transplants. The present study was designed to evaluate the performance of an immunomagnetic cell selection system, including comparison of enzyme and peptide releasing agents and of semi-automated and fully automated selection systems. A total of 74 immunomagnetic CD34
tumors. [1] [2] [3] [4] [5] Among the potential benefits of CD34 + cell enrichment for patients with malignant disease is the concomitant depletion of tumor cells in autologous transplant grafts. [5] [6] [7] [8] CD34 antigen has been shown to be present primarily on progenitor and stem cells, and is not found on mature blood cells or non-Hodgkin's lymphoma, myeloma or most solid tumor cells. 9 In allogeneic transplantation, CD34 selection can provide hematopoietic cells that support hematological recovery and can serve to reduce the number of T cells in transplant grafts. 10, 11 Another advantage of CD34 selection is the ability to secure enriched populations of target cells suitable for ex vivo expansion or gene therapy. [12] [13] [14] The potential clinical utility of enriched CD34
+ cell populations has spurred the development of techniques, reagents and instrumentation systems for positive selection of CD34 + cells. One major approach is immunomagnetic selection, which typically involves specific binding of target cells by anti-CD34 monoclonal antibodies (MoAbs). [15] [16] [17] The resulting cell-MoAb complexes are subsequently captured by second antibodies attached to the surface of magnetic beads. A final release step is then performed to free the target cells from the beads.
With use of optimally designed positive cell selection systems, target CD34
+ cells from patients with various types of disease and from normal donors should ideally be selected in high purity and yield, and the cells should support rapid and reliable hematological reconstitution. Selection should entail little or no alteration to target cell structure or function. Finally, automation of the selection process could potentially allow more rapid, less laborintensive preparation of transplant grafts with greater reproducibility and methodological standardization.
Recently, significant refinements have been introduced in one immunomagnetic cell selection system (Isolex Magnetic Cell Separator System, Baxter Immunotherapy Division, Irvine, CA, USA). One modification is the use of a specific octapeptide rather than the proteolytic enzyme chymopapain to release bead-bound target cells. Identified using high-throughput screening of a combinatorial peptide library, this octapeptide effects cell release by specific competitive binding to the anti-CD34 MoAbs and displacement of the cell surface CD34 antigen resulting in liberation of the target cells into the fluid phase. The attractions of this approach include the low potential for structural or func-tional alteration of the target cells during the release process, specific liberation of only those cells bound to beads via the CD34 antigen, and the release of the target cells free of surface-bound anti-CD34 MoAb. 18, 19 A second recent advance is the introduction of a fully automated system. This system allows cell selection procedures to be performed without operator intervention within a total procedure period substantially shorter than that required with use of the previously introduced semiautomated Isolex system. Total processing time with the fully automated system has been reported to be less than 3 h. 20 The objective of the present study was to evaluate in the clinical setting CD34
+ cell purity, yield and capacity for supporting hematological reconstitution with use of peptide release vs enzyme release and of the fully automated system vs the semi-automated system. This retrospective evaluation was performed using peripheral blood apheresis products collected primarily from patients with a variety of malignant diseases.
Patients and methods

Subjects
Sixty-one patients were evaluated as candidates to participate in this study. Of these, 6/61 (9.8%) were excluded because of failure to achieve a post-mobilization circulating CD34
+ cell level of 20/l, a level associated with a high probability of obtaining sufficient cells for transplantation in a single apheresis collection. 21, 22 CD34 selection procedures were performed on apheresis products from 53 patients and two normal donors between March 1994 and September 1996. All study participants rendered their informed written consent under an ethics committee-approved protocol. The study participants consisted of 33 men and 22 women and averaged 46.6 years of age (range 28-63 years). The majority of patients had hematologic malignancies, predominantly low-grade non-Hodgkin's lymphoma (NHL) or multiple myeloma (Table 1) . Other diseases present among the study participants included breast cancer, Hodgkin's disease, high-grade NHL, and autoimmune disease. The NHL and Hodgkin's disease patients were in first relapse. Of the multiple myeloma patients 14/16 (87.5%) were receiving primary treatment, while the remaining 2/16 (12.5%) had received prior radiotherapy.
All patients were mobilized with a single 3-4 g/m 2 dose of cyclophosphamide and 5 g/kg/day G-CSF starting on day 6 after cyclophosphamide and continuing until the final apheresis collection. When the CD34 + cells in peripheral blood reached 20/l, apheresis collection was initiated. Normal donors were mobilized with G-CSF (10 g/ kg/day), and apheresis was performed on days 5 and 6 of mobilization.
Apheresis products were harvested using a COBE Spectra (COBE Labs, Lakewood, CO, USA) or a Fresenius AS-104 (Fresenius, Oberusel, Germany) blood cell separator. In 52/55 subjects (95.5%) sufficient stem and progenitor cells, ie 20 CD34
+ cells/l, were obtained after one or two leukaphereses, while three collections were necessary in 3/55 (4.5%). For all patients, a back-up apheresis product containing at least 2.5 ϫ 10 6 CD34 + cells/kg was cryopreserved without selection. The starting viability of all cell products was 93% as determined by propidium iodide staining. After CD34 + cell selection all products were cryopreserved and then thawed prior to transplant.
CD34
+ cell selection CD34 + cells were positively selected using either a semiautomated or fully automated immunomagnetic system. 16 In 9/55 subjects (16.4%), the cell selection procedure was performed immediately following the apheresis collection. In the remaining 46/55 (83.6%), the apheresis product was stored overnight at 4°C with 10% autologous plasma. Overnight storage prior to processing did not detectably affect cell viability. Generally, products of two selection procedures were pooled unless the CD34 + cell content of a single product exceeded 10 ϫ 10 6 /kg. The general features of the cell selection process were similar between the semi-automated and fully automated systems. At the start of the selection process nucleated cell count was measured using a Sysmex automated counter (Sysmex Corp., Long Grove, IL, USA). After a platelet wash, the apheresis product was incubated with murine MoAb 9C5 (Baxter Immunotherapy Division) directed against the CD34 cell surface antigen. The CD34 + cells were then rosetted with paramagnetic microspheres (Dynabeads, Dynal, Oslo, Norway) coated with sheep antimouse (SAM) polyclonal antibodies. These second polyclonal antibodies bind to the primary murine MoAbs. The cell/bead complexes were magnetically separated from nontarget cells, and the non-target cells removed. Finally, the CD34 + cells were released from the MoAb/bead complex using either chymopapain or octapeptide and collected. Chymopapain release was used only in conjunction with the semi-automated system.
Semi-automated system
In the cell selection procedure using the semi-automated system, the number of platelets in the apheresis product was reduced by an initial wash with Dulbecco's phosphatebuffered saline (DPBS) containing 1% human serum albumin and 0.2% sodium citrate but devoid of Ca 2+ and Mg
2+
ions. This wash and the subsequent washes to remove unbound antibody were performed in bags in a centrifuge. The cells were centrifuged at low speed for 4 min at ambient temperature, resuspended and incubated with 0.5% human immune globulin for 15 min to reduce nonspecific antibody binding. The cells were next incubated with 2.5 mg of anti-CD34 MoAb 9C5 in a total volume of 100 ml for 15 min at ambient temperature with occasional gentle mixing. Unbound antibody was removed by washing twice with DPBS (800 g, 10 min). MoAb-bound cells were rosetted with paramagnetic microspheres coated with SAM antibodies (4 ϫ 10 9 beads) in the semi-automated system for 30 min at ambient temperature. The system includes a mixing chamber, a motor rocking/mixing element, primary magnets for the capture of beads/rosettes, and a secondary magnet for entrapment of free or released beads. Cell-bead complexes were then washed three times to remove trapped non-target cells. Next, rosetted cells were released from the antibody/beads using either enzyme or peptide, as described below. The released antibody/beads were then captured on the primary magnets. Next, released cells were passed over the secondary magnet to ensure maximal bead capture. The cells were then collected, washed and cryopreserved. In the procedure with the semi-automated system, the platelet wash, antibody incubation and wash steps were performed manually. Cell count was determined after the platelet wash, the MoAb incubation, and the immunomagnetic cell selection. Post-selection cell counts were performed on both the selected and unselected fractions.
Fully automated system
In the cell selection procedure using the fully automated system, every separation step, including the initial platelet wash, was performed automatically in a microprocessorcontrolled instrument with a closed disposable system. Essentially the same incubation times and procedures were employed as those with the semi-automated system; however, all steps were performed in the system's disposable set, which includes a spinning membrane device. The platelet, post-incubation, and post-release washes were performed in the spinning membrane device.
Releasing agents
For enzyme release 8000 pKAT chymopapain (ChymoCell-T, Boots Pharmaceutical, Nottingham, UK) in RPMI 1640 medium (GIBCO Laboratories, Grand Island, NY, USA) were used. The peptide releasing agent consisted of 100 mg synthetic acetyl-Gln-Gln-Gly-Trp-Phe-Pro-Lys-Asp-OH octapeptide (PR34+, Baxter Immunotherapy Division).
Flow cytometry
CD34
+ cells and CD34 + subsets were quantified by leukocyte subset analysis based on single-and two-color flow cytometry analysis. For immunofluorescence analysis, 1 ϫ 10 6 cells from apheresis products and from the nontarget fraction and 2 ϫ 10 6 cells from the CD34 + fraction were suspended in phosphate-buffered saline (PBS) and incubated for 10 min at ambient temperature with one, two or three MoAbs conjugated with fluorescein-isothiocyanate (FITC) or phycoerythrin (PE) and directed against the following lineage or activation antigens: CD45; CD34 (HPCA 2-PE); CD3; CD2; CD7; CD19; CD38 and DR (Becton Dickinson, France). Isotype-identical antibodies (IgG1, IgG2a, and IgG2b FITC/PE conjugated, Becton Dickinson, France) served as controls. After washing, 50 000 events were acquired for single-and double-color analysis for initial and non-target cells, and 10 000 events for the selected CD34 + cell fraction. Immunofluorescence analysis was performed using a five parameter FACScan (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA). The proportion of positive cells was calculated following the subtraction of nonspecific events in the negative control. The absolute number of CD34 + progenitors, T cells (CD3 + , CD2 + ), and B cells (CD19 + ) was determined by multiplying the frequency of positive cells by absolute cell count. CD34 + FACS staining was used as an assay for competitive release by purified peptide following formation of a 9C5 MoAb/cell complex.
Data analysis
Data were analyzed using SPSS 7.5 statistical software (SPSS, Inc., Chicago, IL, USA). Quantitative results are presented as medians and ranges. The statistical significance of between-group differences in quantitative results was determined by Kruskal-Wallis one-way analysis of variance or Mann-Whitney U test. Correlation analysis was performed using the Spearman rank order method. Null hypotheses were rejected at the 0.05 ␣ level.
Results
Apheresis and selection
Fifty-three patients and two normal donors underwent apheresis, and the resulting apheresis products were used to perform a total of 74 CD34
+ cell selection procedures ( Table 1 ). The total number of CD34 + cells in the starting products varied between 50-2846 ϫ 10 6 , or 0.9-33 ϫ 10 6 cells/kg. The starting apheresis products contained 6.5-120.9 ϫ 10 9 total nucleated cells.
Purity and yield among different groups of subjects
Median purity and yield of CD34 + cells in all 74 cell separation procedures were 88.9% (28.1-99.7%) and 44.7% (10.0-94.0%), respectively. As shown in Figure 1 , purity and yield did not differ significantly among specimens from low-grade lymphoma patients, myeloma patients and other subjects. Median purity observed in 31 selections of apheresis products from lymphoma patients was 84.0% (28.1-98.5%) compared with 94.5% (52.4-99.7%) in 19 selections of apheresis products from myeloma patients and 93.7% (36.0-99.0%) in 24 procedures using apheresis products from other types of subjects. Corresponding median yield results from the procedures using apheresis products from lymphoma, myeloma and other subjects were 42.3% (16.0-76.0%), 38.2% (29.0-94.0%), and 50.7% (10.0-94.0%), respectively. For the 57 procedures with enzyme as the releasing agent and the semi-automated cell separation system, there were also no significant differences in purity and yield depending on the source of apheresis products (lymphoma, myeloma and other).
Purity and yield with different releasing agents
In 66 selection procedures with the semi-automated system, enzyme release was employed in 57 procedures and peptide release in nine. Median starting percent CD34 + cells prior to enzyme release (1.6%; 0.4-5.4%) was not significantly different than that before peptide release (2.0%; 0.5-8.3%). With the enzyme release procedure, the median CD34 + cell purity of the selection product was 85.8% (28.1-99.7%), as shown in Figure 2a . Median yield was 41.1% (10.0-94.0%), which provided a median of 3.04 ϫ 10 6 CD34 + cells/kg per procedure (Figure 2b ). Median purity (98.5%; 81.0-99.0%) with the peptide releasing agent was significantly higher (P = 0.002) than that using enzyme release (Figure 2a) . Yield with peptide release (48.0%; 29.0-94.0%) was also higher than that with enzyme release ( Figure 2b) 
Purity and yield with different cell selection systems
Purity and yield were compared in nine selection procedures with the semi-automated cell selection system and eight with the fully automated system. All 17 of these selection procedures were performed using the peptide release method. There was no significant difference in median starting percent CD34 + cells prior to semi-automated (2.0%; 0.5-8.3%) vs fully automated (2.1%; 0.4-3.5%) cell selection. High CD34 + cell purity was achieved both with use of the semi-automated (98.5%; 81.0-99.0%) and fully automated (95.4%; 64.9-97.9%) cell selection systems (Figure 3) , and there was no statistically significant purity difference between the two systems. As shown in Figure  3 , yield with the fully automated system (55.4%; 16.0-91.3%) was modestly but not significantly higher than that with the semi-automated system (48.0%; 29.0-94.0%), corresponding respectively to medians of 4.7 ϫ 10 6 CD34 + cells/kg and 8.2 ϫ 10 6 CD34 + cells/kg. Thus, both the semiautomated and the fully automated systems yielded more than 2 ϫ 10 6 blood-derived CD34 + cells/kg, a quantity generally recommended for rapid and reliable hematological recovery.
23,24
Leukocyte subset analysis
Flow cytometry analysis of CD34
+ cell subsets within the positively selected CD34
+ cell populations revealed few immature progenitors, ie those lacking the cell surface antigens CD38 and DR (CD34 + CD38 Ϫ 6.5%; CD34 + DR Ϫ
1.6%). Others have reported the presence of CD34 + CD19
+ cells in BM products 25 and lesser amounts in the peripheral blood. [26] [27] [28] This phenotype was detectable in the apheresis but not the selection products in the present study. CD34 + CD7 + was not detectable, and this observation is consistent with the low percentage of this phenotype reported by Inaba et al 29 in peripheral blood. The enriched CD34 + cells were found to be low in CD45.
Flow cytometry
Cells with a low density of CD34 antigen on the cell surface were observed primarily in the non-selected fraction ( Figure 4) + cells/kg). All but the 16 myeloma patients received G-CSF following transplantation. Days to recovery of Ͼ1000/l white blood cells (WBCs) and Ͼ50 000/l platelets are presented in Table 2 . In the present study no cases of graft failure or graft rejection were observed during a follow-up period of 2-24 months.
Among all patients recovery of Ͼ1000/l WBCs occurred at a median of 12.0 days (7.0-26.0 days), and 90% of patients achieved Ͼ1000/l WBC recovery within 17.0 days ( Table 2) . Median time to Ͼ1000/l WBC recovery was 3 days longer in myeloma patients (P Ͻ 0.0005) compared with lymphoma and other patients. This difference is likely a reflection of the post-transplant G-CSF administered to the lymphoma and other patients but not the myeloma group. Neutrophil engraftment has been shown to be significantly accelerated by post-implant G-CSF administration. [30] [31] [32] Median WBC recovery time ranged from 11.0 days to 12.0 days among patients stratified by releasing agent and cell selection system. No significant between-group differences were evident with different releasing agents or cell selection systems.
Median time to platelet recovery, defined as Ͼ50 000/l platelets, in all patients was 14.0 days (9.0-70.0 days), and there were no significant differences among the three diagnostic groups in platelet recovery time. Median platelet recovery time with peptide release (12.0 days; 10.0-13.0 days) was significantly shorter (P = 0.001) by 4.0 days compared with enzyme release (16.0 days; 10.0-70.0 days). Median time to Ͼ50 000/l platelets of 14-15 days has been previously reported by other investigators following transplantation of CD34 + cells. 1, 33 Thus, the difference in platelet recovery time in the present study appears to reflect CD34 + cells/kg or more has been shown to be associated with faster WBC and platelet recovery than that with lower numbers of CD34 + cells. 34, 35 Thus, the observed difference in platelet recovery time between the peptide and enzyme releasing agents could have reflected the higher median CD34
+ cell number transplanted in the peptide group rather than a difference related to releasing agent per se. However, no significant correlation was evident between number of CD34 + cells transplanted and platelet recovery time in either the peptide (P = 0.338) or enzyme (P = 0.100) group. In addition, if the 11 enzyme patients receiving Ͻ2.0 ϫ 10 6
CD34
+ cells/kg are excluded from analysis, significantly shorter platelet recovery time is still evident in the peptide group (P = 0.004).
Discussion
The present clinical study provides evidence that immunomagnetic selection can provide CD34
+ cells of high purity in sufficient numbers for transplantation. The resulting CD34 + cell grafts reliably supported rapid engraftment of white blood cells and platelets in patients with both hematologic malignancies and solid tumors. Use of a highly specific peptide releasing agent resulted in significantly higher CD34 + cell purity. With a newly developed fully automated immunomagnetic CD34
+ cell selection system purity, yield and time to engraftment were similar to those with a semiautomated system; however, the time needed to perform selection procedures was reduced by more than half, and the need for operator intervention at multiple steps during the course of the procedures was eliminated. Tumor cell depletion results after immunomagnetic selection in myeloma and lymphoma patients will be the subject of a future report.
The incorporation of a specific peptide as releasing agent in immunomagnetic cell selection procedures appears to confer major advantages over enzymatic release. Among these is the avoidance of structural modifications to the target cell. Chymopapain has been shown to modify the CD34 + cell surface. 5, 36 In contrast, peptide release has been found by scanning electron microscopy to result in a highly homogeneous cell population with complete surface integrity and free of magnetic beads. 18 Murine MoAbs recognize different epitopes of the CD34 sialoglycoprotein. These epitopes can be grouped into three classes by their differing sensitivities to the enzymes neuraminidase, chymopapain and glycoprotease. Chymopapain cleaves the CD34 epitope recognized by the 9C5 antibody (class II) used in the Isolex system, but not the epitope recognized by the HPCA-2 antibody (class III) used in flow cytometry analysis. Thus, chymopapain treatment does not interfere with post-selection quantification of CD34 + cells. However, additional proteins on the cell surface are modified by chymopapain, including the adhesion molecule L-selectin and epitopes recognized by monoclonal antibodies directed to CD8, CD14, CD33, CD44, CD45RA and CD71. 5, 36 A number of these proteins are re-expressed within 24-48 h of treatment. 37 Nevertheless, even transient alterations of the target cell surface should ideally be avoided if possible.
Another drawback of enzymatic release is the possible presence of trace amounts of residual chymopapain in the transplant graft. No reports of chymopapain-related hypersensitivity reactions in transplant patients have thus far appeared following the use of enzymatic release. The potential for adverse reactions is, however, exemplified by chymopapain intradiscal therapy, which with high chymopapain concentrations has been associated with allergic responses, including anaphylactic shock. 38 Latent sensitization to chymopapain has been linked to the ingestion of papaya. 39 The synthetic octapeptide used in the present study was identified as the result of screening more than 10 10 peptides in a combinatorial phage display library. 40 This peptide has been shown to be nontoxic and non-antigenic in preclinical models. 19 The peptide releases bead-bound CD34 + cells via a highly specific competitive binding mechanism. Specific high-affinity binding of the peptide to anti-CD34 MoAb epitope results in transition of the CD34 + cells to the unrosetted state, releasing the entire bead/antibody complex from the cell surface. CD34 + cells released using the octapeptide have been shown to be free of both residual surface antibody and magnetic particles. 41 Cell surface antigens remain intact, thus facilitating immunophenotypic analysis or additional immunoselection. Furthermore, after peptide release the selected CD34
+ cells have been reported to remain viable and fully functional, with excellent ex vivo expansion capacity. 42 Significantly greater ex vivo expansion capacity has been observed after peptide vs chymopapain release.
Among the CD34 + cell surface proteins preserved intact by the octapeptide is L-selectin. 5 The number of CD34 + cells co-expressing L-selectin has been found to correlate significantly better with time to platelet recovery than total number of CD34 + cells. This observation has prompted the suggestion that L-selectin is involved in the homing of CD34 + cells after transplantation. 43 This putative role of Lselectin in homing could account for the accelerated platelet recovery observed with peptide release, since peptide but not chymopapain preserves cell surface L-selectin. However, the number of observations indicating accelerated platelet recovery was comparatively small, and different median CD34
+ cell dosages were administered. Consequently, the accelerated platelet recovery in the present study should be considered a preliminary observation only.
The fully automated selection system reduces the time required to process an apheresis product to 3 h compared with the 7 h for the semi-automated system. The fully automated system eliminates multiple procedural steps requiring operator intervention, reducing the labor intensiveness of cell selection as well as allowing greater standardization of procedures. Increased standardization can be expected to improve the reproducibility of results and allow data from different investigational centers to be more readily compared. The fully automated system also reduces the risk of microbial contamination.
